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Abstract
Objective: To investigate the therapeutic potential and mechanism of action of the mimotope of PGE2 receptor
EP4 (PBP, named by our team) screened by phage displaying technique in the treatment of adjuvant-induced
arthritis (AA).
Methods: Freund’s complete adjuvant-induced arthritis was induced in Wistar rats. At the first clinical sign of
disease, mice were given with daily injections of PBP or saline for 21 days. Disease progression was monitored by
measurement of paw swelling. Inflammation and joint destruction were assessed histologically. The IL-1b and
TNF-a were studied by ELISA in the ankle steeps of arthritis model. The degree of proliferation and apoptosis of
synoviocytes of RA patients were assessed by CCK-8 kit and AnnexinⅤ-FITC/PI respectively.
Results: PBP-treated animals displayed significantly less cartilage and bone destruction than model controls. Tumor
necrosis factor a and IL-1b expression were reduced after PBP treatment. The proliferation and apoptosis of
synoviocytes of RA patients were influenced by PBP.
Conclusions: The data support the view that PBP is a potential therapy for RA that may help to diminish both
joint inflammation and destruction. And the activities of PBP are related with the effect on synoviocytes directly.
Introduction
RA is characterized by systemic and local inflammation
resulting in cartilage and bone destruction. Non-steroi-
dal anti-inflammatory drugs (NSAIDs), which represent
an effective therapy for treating RA, elicit their effects
by inhibiting cyclooxygenase (COX) activity and block-
ing the downstream production of prostaglandin, includ-
ing prostaglandin E2 (PGE2). And the major medicine
treating RA is COX-2 selective inhibitor. However, this
kind of medicine has side-effects such as cardiovascular
effects [1,2], which have limited its use. PGE2 is the
most important molecule in the pathogenesis of rheu-
matoid arthritis [3], which can be secreted by a lot of
cells including macrophage cells and synovial fibroblast.
Moreover, PGE2 is one of the main products of cycloox-
ygenase in a number of physiological settings. The
diverse effects of PGE2 may be accounted for in part by
the existence of four receptors, designated EP1, EP2,
EP3, and EP4 [4,5], and heterogeneity in the coupling of
these receptors to intracellular signal transduction path-
ways. In RA, EP2 and EP4 receptors, especially EP4
receptor [6], are the major ones which couple to the
Gs-type G protein leading to stimulation of cAMP.
Then specific mimotope of PGE2 receptor may pre-
vent the binding between PGE2 and receptor, which
may be an effective treatment method on RA. Phage dis-
playing technology has abroad application in the study
of reorganization of protein molecules, development of
new vaccine and new drug. Its greatest advantage is pro-
viding some libraries where the target-specific binders
can be selected conveniently. So we have used the phage
displaying technique to select C-X7-C peptides with
PGE2 as the target and named these peptides PBPs
(PGE2 binding peptide) and regarded the PBPs as a
mimotope of EP4 [7]. Moreover, some reports have
demonstrated that the key binding sites between PGE2
and receptor are related with arginine and threonine
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any medium, provided the original work is properly cited.[8,9]. So we have selected one peptide of which the
sequence is CANRTSKNC to synthesize.
In the present study, we generated RA rat models and
treated them with PBP. It was found that this treatment
could reduce arthritis severity and footpad swelling. To
investigate the therapeutic effect and the mechanism of
this mimotope in RA, we detected its anti-inflammatory
effect furthermore and demonstrated this mechanism in
vivo and in vitro.
Materials and methods
Animals
Male Wistar rats weighing 160 g-180 g, were purchased
from the animal center of our university. All animals
were placed at a controlled temperature (22°C-28°C),
and a regular light/dark cycle (6:00 to 19:00 h, light),
and all animals had free access to food and water.
Chemicals
PGE2 was bought from Jingmei Lt and PGE2 ELISA kit
was from the Suzhou Hematology Research Centre.
ELISA kits for IL-1b and TNF-a were Ebioscience pro-
ducts. Celecoxib was purchased from Pfizer Pharmaceu-
ticals Limited product. All enzymes were from TaKaRa
Biotechnology (Dalian) co.ltd. Freund’s complete adju-
vant (FCA) was from Beijing Dingguo Biotechnology co.
ltd. CCK-8 kit was purchased from Dojindo.
Molecular modeling
Theoretical structure model of PBP and PGE2 were
obtained using the HOMOLOGY module of the
Insight II 2000 software firstly. The surface and interior
between PBP and PGE2 were distinguished and the best
connection between them was determined with compu-
ter graphics technology. The most acceptable solution
was determined and optimized using Discover Module
of Insight II (2000) software package. The Discover_3
program was used to generate the low-energy conforma-
tion of the complex.
Induction and treatment of arthritis in rats
Rat AA was induced as previously described [10].
Briefly, The rats were immunized by subcutaneous
injection into the left-hind paw with 0.1 ml Freund’s
complete adjuvant (FCA), containing 10 mg heat-inac-
tive BCG in 1 ml paraffin oil. All procedures were
approved by University Committee on the use and care
of laboratory animals. Arthritis usually developed 6 days
later after immunization. The rats were considered to
have arthritis when significant changes of redness and/
or swelling were noted in the digits or other parts of the
paw. The animals were assigned to one of five groups at
random, in which they were treated intraperitoneally
with 10 ug/kg, 20 ug/kg, and 40 ug/kg PBP per
injection, with 12.5 mg/kg celecoxib 0.5 ml as positive
control, with 0.5 ml saline as negative control. Treat-
ment was started on the seventh day after this disease
was induced. All groups were treated daily for 21 days.
Thereafter, the rats were killed by cervical dislocation
and the hind paws and sera were collected and used
for further analysis. The in vivo experiments were
performed with 6 rats per group.
Evaluation of arthritis activity
Rats were inspected daily for signs of arthritis by
an independent observer who was not aware of the
treatment. After 21 days of treatment, rats were killed
and their paws were processed for histopathological
evaluation.
ELISA for inflammatory cytokines IL-1b and TNF-a in
ankle steeps
In order to detect the cytokine level in the ankles, whole
ankle joints were cut after rats were anaesthetized and
dipped in PBS for 24 h after the skin and parenchyma
were cut open. The ankle steeps were collected and
stored in a -20°C refrigeratory for the next tests. TNF-a
and IL-1b in the samples were measured using enzyme-
linked immunoassay kit (ebioscience company rats
TNF- a and IL-1b ELISA kit), according to the manufac-
turer’s protocol. Briefly, ankle steeps were added to wells
from 96-well plate precoated with 100 ul/well capture
antibody and incubated for 2 h at 37°C. After wash,
detection antibody were added and incubated for 1 h at
37°C. After another wash, horseradish peroxidase (HRP)
labeled anti rat IgG goat antibodies were added and also
incubated for 2 h at 37°C, After the final wash, the pre-
sence of HRP-labeled Abs was revealed by addition of
o-phenylenediamine (OPD) and the reaction was
s t o p p e dw i t hs u l f u r i ca c i d( 2 N ) .T h ec o l o r a t i o nw a s
evaluated by optical density at 490-630 nm.
Histology
Whole ankle joints were fixed in 5% formalin at 4°C for
24 h. Subsequently, joints were decalcified in 10% ethy-
lene diamine tetraacetate (EDTA) in buffered formalin
(5.5%) for 4 weeks, and processed for histology by routine
paraffin embedding, sectioning (4 μm), and staining using
hematoxylin and eosin (H&E) and examined for the
degree of synovitis and bone erosions by microscopic
evaluation in a blinded manner as described earlier. Bone
erosions were scored using a semiquantitative scoring
system from 0 to 4 (0 = no erosions, 4 = extended ero-
sions and destruction of bone).
Isolation of synoviocytes
Synovial tissues were obtained from RA patients who
met the American Rheumatism Association criteria for
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g e r y( 5w o m e n ,2m e n ;5 5±2y e a r s ) .T h es t u d yw a s
approved by the local ethics committee, and informed
consent was obtained from each patient enrolled. The
synovial samples were digested and subsequently cul-
tured as described by Zimmermann et al [11]. Synovial
fibroblasts were isolated by enzymatic digestion of syno-
vial tissues obtained. Synovial tissues were minced into
3-5 mm pieces and treated for 4 h with 4 mg/ml of
typeⅡcollagenase (Sigma Chemical Co., St Louis, MO,
USA) in Dulbecco’s modified Eagle’sm e d i u m( D M E M ;
Gibco BRL., Grand Island, NY, USA) at 37°C in 5%
CO2. Dissociated cells were then centrifuged at 2000
rpm and resuspended in DMEM supplemented with
20% fetal calf serum (FCS), 100 units/ml penicillin, and
100 mg/ml streptomycin, and plated in 6 well culture
plates. The next day, cultured plat was vigorously rinsed
to remove non-adherent cells with fresh DMEM, and
adherent synovial fibroblasts were cultured in DMEM
supplemented with 10% FCS. The cultures were kept at
37°C in 5% CO2, and the medium was replaced every 4
days. The cells were morphologically homogeneous and
had the appearance of fibroblast, with typical bipolar
shown. We named them as HSY (Human Synoviocyte
Yan). All the experiments described below were con-
ducted using cells at the 4-10 passage. The experiments
were done as follows.
Synoviocytes proliferation assay
The synoviocytes were suspended in DMEM medium
with 10% FCS at a concentration of 1 × 10
5 cell/ml. The
cell suspension of 100 μl were added to 96-well flat-bot-
tomed culture plate and incubated at 37°C, in 5% CO2
for 24 h. After the cells adhered, PBP with different con-
centrations were added to the well, 5 μM, 2.5 μM, 1.25
μM, 0.625 μM, 0.3125 μM, and DMEM with 10% FCS
as a negative control and incubated at 37°C, in 5% CO2
for 48 h. Then incubation were added with 10 μlW S T -
8 from CCK-8 kit (Dodindo, Japan) to each well, oscil-
lated for 1 min on oscillator and incubated at 37°C and
in 5% CO2 for 1.5 h continuously. After incubation, the
absorbance (A) was measured at 450 nm.
Apoptosis detection kit (Annexin V binding)
The assay was performed according to the instructions
of the manufacturer. FLS were seeded at 1 × 10
5cells/
well and incubated for 24 h, then were treated with 5
μM PBP and 40 μM celecoxib, and PBS (phosphate-buf-
fered saline) as a negative control. After 24 h, Cells were
trypsinized, counted and sedimented, then washed with
cold PBS, and resuspended in 500 μl binding buffer.
Fluorescein isothiocyanate conjugated Annexin V (10 μl)
and PI (10 μl) were added to each samples, and the mix-
ture was incubated at 4°C in the dark for 5 min. Then
the cells were immediately subjected to FACS analysis
(BD FAC-S Calibur, USA).
Hochest 33342 and PI staining
Cells growing in exponential phase were seeded at 2.5 ×
10
4 cells in 2 ml of DMEM with 10% FCS in a 6 well
culture plate with a cover slip and incubated in a 5%
CO2 atmosphere. Cells were exposed to 5 μMP B Pa n d
40 μM celecoxib, and PBS as a negative control. The
morphology of treated and untreated cells was examined
following incubation for 72 h. Cells were washed
with PBS three times and then stained with 10 μl
Hoechst33342 nuclear dye (working concentration was 5
μg/ml) in 2 ml of DMEM for 10 min at 37°C. After
washing with PBS 3 times, cells were added with 2 ml
new of DMEM and 30 μl PI (working concentration was
1.5 μg/ml) for 10 min at 4°C. After another washing
with PBS for 3 times, images were obtained by confocal
fluorescence microscope (Olympus-FV1000, Japan). The
average of the apoptotic cells in each of the respective
groups was determined as a percentage of the control
(untreated cells).
Statistical analysis
Differences between treatment groups were tested by
one-way ANOVA and unpaired two-tailed Student’ test.
The data were expressed as the mean ± SEM. Analysis
of variance of repeated data measured with SPSS 13.0,
and P values less than 0.05 at 95% confidence level were
considered significant.
Results
3-D modeling structures of PBP and PGE2
The 3-D complex structure suggested that there
formed hydrophobic interaction between PBP and PGE2
(Figure 1A and 1B), and the interaction energy between
PBP and PGE2 was -11.4036 KJ/MOL, in which the
VDH is -5.38675 KJ/MOL. So certain conclusions and
predictions could be drawn from the results that the
interaction between PBP and PGE2 had a relatively
stable structure.
PBP reduces the paws inflammation of AA
To examine whether PBP therapy could be effective in
the treatment of AA, rats were given with a daily intra-
peritoneal injection of various dosages of PBP or saline
for 21 days. All animals were treated on the seventh day
after immunization. All groups treated with PBP showed
a 70% decrease in paw swelling compared to controls (P
< 0.05) (Figure 2). There was no clear dose dependency
in peptide treatment groups, suggesting that all dosages
were in the therapeutic range with regard to effects on
clinical signs of arthritis. The effect of PBP treatment on
synovial inflammation was also assessed in histology.
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at all by H&E (Figure 3A) from histopathology of the
ankle joints, while model groups showed heavy cell infil-
tration, neovessel growth, synovial cell proliferation, and
pannus formation in tissues of AA rats (Figure 3B). And
peptide treatment groups showed a marked destruction
and infiltration compared with model groups (Figure
3C). It was found the histologic score decreased after
PBP treatment compared with model groups (P < 0.05)
but did not reach the normal level (Figure 3E).
PBP pervasively suppresses TNF-a and IL-1b in
inflammatory tissues of AA
In particular, cytokines secreted from synoviocytes, such
as TNF-a and IL-1, were considered major determinants
in the perpetuation of arthritis [12]. TNF-a is a pro-
inflammatory cytokine which may induce the prolifera-
tion of synoviocytes and enhance their production of
cytokines such as TNF and IL-1 in situ, which largely
show the pathology of arthritis. It also largely accounts
for the pathology of autoimmune-related arthritis [13].
PBP PGE22
A B
Figure 1 The optimized complex structure of PBP and PGE2 using molecular docking and molecular dynamics methods.S t i c ka n d
sphere model were showed in A and B respectively.
A B
Figure 2 Effects of the PBP on suppression of joint and tissue swelling in AA. The paw swellings of rats were evaluated by an inelastic
tape measure. All groups treated with PBP showed a 70% decrease in paw swelling compared to model controls, P < 0.05. And peptide
treatment groups showed a marked destruction and infiltration compared with model groups. (A: the primary swelling of ankle joint. B: the
secondary swelling of ankle joint).
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was decreased in the synovium of AA by PBP. ELISA
showed that the level of TNF-a and IL-1b in the ankle
steep were reduced by intraperitoneal PBP (Figure 4).
There was also no obvious dose dependency in peptide
treatment groups (data not shown).
Effects and Mechanism of PBP Inhibitors on Synovial
Synovial hyperplasia was thought to play an important
role in the development of AA which was caused by an
increased rate of proliferation of FLS. Through CCK-8
assays, we had observed that PBP treatment groups could
inhibit the synovial fibroblast proliferation compared with
non-PBP groups. The inhibitory percent could arrive at
about 50% (Figure 5). This was the evidence that PGE2
might be a mitogen which could promote synovial fibro-
blast proliferation. Therefore, this peptide through
screening phage library with PGE2 as a target could inhi-
bit PGE2 to interact with its receptor EP4 [6].
On the other hand, two methods were used to value
the effects of PBP on FLS apoptosis. From the pictures
of laser scanning confocal fluorescence microscope
(Figure 6A-6C), we had observed viable cells, apoptotic,
and necrotic cells. Moreover, the Hoechst33342 dye
stained the nuclei of all cells; therefore apoptosis might
show nuclear changes such as chromatin condensation
and nuclear fragmentation. So in PBP treatment groups,
we could see these changes (see what was directed by
arrow in Figure 6B). While PI uptake indicated the loss
of membrane integrity characteristic of necrotic and late
apoptotic cells because PI was excluded from viable and
early apoptotic cells (Figure 6C); in combination with
fluorescence microscopy, selective uptake of the two
dyes allowed one to monitor the induction of apoptosis
in intact cultures and to distinguish it from non-apopto-
tic cell death (necrosis). Necrosis was characterized in
this system by nuclear PI uptake without chromatin
condensation or nuclear fragmentation, but this did not
reach statistical significance. We also used AnnexinV-
FITC and PI double staining with FACS to detect the
effect of PBP on FLS apoptosis. We could see the per-
cent of early apoptosis cells was 6.5 ± 2.2% in PBP treat-
ment groups which increased by 1.7% than FLS negative
control groups. While the percent of later apoptosis and
necrosis was 14.05 ± 3.0, which exceeded FLS negative
control groups by 4.05% (Figure 6D and 6E).
C D
A B
Figure 3 Changes of the histological morphology of rats ankle joints by H&E staining. The effect of PBP treatment on synovial
inflammation was also assessed by histology. Wild-type rats showed no inflammation and destruction at all by H&E (A) from histopathology of
the ankle joints, while model groups showed heavy cell infiltration, neovessel growth, synovial cell proliferation, and pannus formation in tissues
of AA rats (B). Peptide treatment groups showed a less marked destruction and infiltration compared with model groups (C). Celecoxib
treatment groups showed the same change as peptide treatment (D). (E): Effect of PBP on the clinical and pathological manifestations of rat
adjuvant-induced arthritis. Note: 0: normal; 1: the extent of inflammatory cells’ infiltration to the joint tissues; 2: synovial lining cell hyperplasia; 3:
pannus formation; 4: joint cartilage layers destruction. *; P < 0.05 compared with normal. #; P < 0.05 compared with model.
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In 2002, McCoy and their groups showed that prosta-
glandin EP4 receptor, but not EP1, EP2, EP3 receptor-
deficient mice decreased the incidence and severity of
disease in the mouse arthritis model, suggesting that the
mimotope of the prostaglandin EP4 receptor might pro-
vide novel agents for the treatment of rheumatoid
arthritis [2]. Moreover several researchers had found
that mimotope of the prostaglandin EP4 receptor such
as CJ-042,794 [6,14] had the comparable effects on inhi-
biting inflammation process compared with non-selec-
tive COX inhibitor (piroxicam) and selective COX-2
inhibitor (rofecoxib). So how to select the mimotope of
the prostaglandin EP4 receptor became the key point
for searching effective medicines [15,16].
Through phage-peptide library, high affinity and speci-
fic peptides can be isolated which could be made into a
new type medicine of treating diseases [17,18]. Phage
displaying technology is a high-throughout screening
(HTS) assay for studying the binding site of ligands and
receptors, searching for the ligand molecules with high
affinity and detecting the dimensional structure epitopes
of unknown protein, which has an abroad application in
the study of reorganization of protein molecules, devel-
opment of new vaccine and new drug. Moreover, it
plays an important role on the simulating epitopes,
identifying the major animos between proteins interac-
tion. The Ph.D-C7C is to link the genotype of short
peptide displaying on the phage surface with the pheno-
type closely. Rapid enrichment of library clones encod-
ing binding polypeptides is achieved by phage library
incubation with a target followed by removal of
the non-reacting phage and amplification of binder
clones in the host bacteria [19-21]. Usually, three to five
rounds of panning are sufficient to enrich for binding
peptide sequences. In our studies, we have selected the
TNF-α
A B
IL-1˟ ˟
Figure 4 Concentration of IL-1b and TNF-a in joint. (x ±s ,n=6 ) . ELISA showed that the level of IL-1b and TNF-a in the ankle steep were
reduced by intraperitoneal PBP. *; P < 0.05 compared with normal. #; P < 0.05 compared with model.
Figure 5 Effects of PBP on synoviocytes viability. Synoviocyte
viability was assessed by CCK-8 assay, with control cells taken as
100%. Synoviocytes were incubated for 24 h with PBP (0.3125 μM,
0.625 μM, 1.25 μM, 2.5 μM, 5 μM).
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named by PBPs. Moreover, we had employed the Mole-
cular Docking technology with Insight II 2000 software
in SGI working station to analyze the three-dimensional
structure of PBP and PGE2 [22]. The lower energy indi-
cates the high affinity between these two molecules,
which provides the theoretical foundation for the next
research.
With respect to the potential as a drug target in treat-
ing RA, our findings indicate that selective inhibition of
PGE2 EP4 receptor will decrease the inflammation in
ankles. This should markedly shift the balance away
from the bone resorption that mediates osteolysis. It is
of interest to see if future studies designed to investigate
the effects of Cox-2 inhibition on the various other fac-
tors that stimulate inflammation and bone resorption
in fibroblasts, as well as clinical trials, support this
paradigm.
Although several labs have been able to demonstrate
that Cox inhibitors can effectively block PGE2 synthesis,
it has been demonstrated that this treatment can inhibit
pro-inflammatory cytokine synthesis (e.g. TNF-a and
IL-1) by these cells [23,24]. Thus, it remains unclear
how NSAID effectively inhibit synoviocytes proliferation.
Synoviocytes were the ultimate targeting cells of patho-
logical change of arthritis [25]. PGE2 is an autocrine fac-
tor in rheumatoid arthritis, so its effect on the
proliferation and apoptosis of synoviocytes should not
be neglected. Through analysis of our results, it can be
found that the prevention of interaction between PGE2
and its receptor EP4 by PBP can affect the cells prolif-
eration in some degree, which is extremely beneficial for
the treatment of RA.
Whereas IL-1 and TNF might be more important in
the processes leading to cartilage and bone destruction
and in limiting mechanisms involved in cartilage repair
[26-28]. Tumor necrosis factor (TNF) antagonists (adali-
mumab, etanercept, infliximab) and TNF inhibitors (cer-
tolizumab pegol, golimumab) have been approved under
the development respectively [29,30]. Interleukin 1
(IL-1) antagonist (anakinra) has been approved to treat
RA [31]. So these two cytokines are better value to
A B C
Figure 6 Synoviocytes apoptosis induced by PBP. A-C: Apoptosis detected using cofocol fluorescence microscope. Synoviocytes were
incubated for 24 h with 5 μM PBP (B) and 40 μM celecoxib (C), and PBS as a negative control (A). They were stained by Hoechst33342 and PI.
We had observed that viable cells, apoptotic, and necrotic cells. On the one hand, the Hoechst33342 dye stained the nuclei of all cells; therefore
apoptosis might show nuclear changes such as chromatin condensation and nuclear fragmentation. So in PBP treatment groups, we could see
these changes (see what was directed by arrow in B and C). On the other hand, PI uptake indicated the loss of membrane integrity
characteristic of necrotic and late apoptotic cells. D-F: Apoptosis detected using FACS. Synoviocytes were incubated for 24 h with 5 μM PBP
(E) and 40 μM celecoxib (F), and PBS as a negative control (D). They were stained by AnnexinⅤ-FITC and PI. Then, the viability was determined
using the FCM. AnnexinⅤ-FITC (-) and PI (-), living cells; AnnexinⅤ-FITC (+) and PI (-), early apoptotic cells; AnnexinⅤ-FITC (+) and PI (+), late
apoptotic cells and necrotic cells. The numbers showed the percentages of each fraction.
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for treating the disease. It can be also found that PBP
contributed to the reduction of pro-inflammatory cyto-
kines TNF-a and IL-1, which maybe another mechan-
ism of its anti-arthritis effects.
In conclusion, our results provide new relevant data of
the mimotope activities of PGE2 receptor. PBP as a
mimotope of EP4 has anti-inflammatory activities, which
has been proved in vivo and in vitro.S ot h ep e p t i d e
screened by phage displaying technique has relevant
therapeutic potential to the treatment of arthritis
diseases.
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